Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market

Journals

REMEDIUM

The periodical about the pharmaceutical and medical equipment markets

ROSSIYSKIE APTEKI

(Russian pharmacies) - specialized periodical edition for pgarmacy professionals

MEDITSINSKY SOVET

Medical Council - Scientific Journal for Physicians


Home / News

14.08.2007

STADA: Strong growth continues

According to the financial figures published by STADA ARZNEIMITTEL AG today on August 14, 2007, the strong growth of the Group in sales and earnings has continued in the first half of 2007.

The preliminary estimates of the ad hoc release from July 2, 2007 were thereby unconditionally confirmed. Thus, from the Executive Board's current perspective, the twelfth record year in a row in sales and earnings is expected for 2007.

Hartmut Retzlaff, Chairman of STADA's Executive Board, comments on STADA's half year results with great satisfaction: 'The clear double-digit growth rates in sales and income show that we continue to be able to turn the growth potential of the markets into own growth. This applies in particular to the international business, but currently also to Germany. Here, our generics sales line ALIUD PHARMA developed exceptionally well particularly in the second quarter of the current fiscal year. And through the recently carried out acquisition of the Russian pharmaceutical group MAKIZ in the current third quarter, we have further strengthened our international presence in the important growth market Russia. STADA thus continues to be on a clear growth course.'

High increase in Group sales Group sales increased by 27% to EUR 737.4 million in the first six months of the current fiscal year (first half of 2006: EUR 580.0 million). The corresponding organic sales growth (without sales contributions from acquisitions, disposals, and products given up in the previous twelve months) amounted to 12% in the first half of 2007.

Sales of the significantly larger core segment, Generics, rose by 34% to EUR 554.9 million in the first half of 2007 (first half of 2006: EUR 414.1 million). Thus, Generics contributed 75.2% to Group sales in the first six months of 2007 (first half of 2006: 71.4%). Sales of the second core segment Branded Products increased by 10% to EUR 142.1 million in the first half of the current fiscal year (first half of 2006: EUR 129.7 million). Thus, Branded Products had a share of 19.3% in Group sales in the reporting period (first half of 2006: 22.4%).

Sales from STADA's international business activities rose, as expected, at a higher rate as compared to Group sales in the first six months of 2007 and now amount to 60.5% of Group sales (first half of 2006: 56.9%). This development continues to confirm the Group's long-term growth-oriented course of internationalization.

Clear increase in net income Net income was increased by 38% to EUR 58.3 million in the first half of 2007 (first half of 2006: EUR 42.2 million). Earnings per share thus amounted to EUR 1.00 in the first six months of the current fiscal year (first half of 2006: EUR 0.79). Here, it must be taken into consideration that the average number of STADA shares increased by 9% as compared to the first half of 2006 due to the exercise of options since then. Diluted earnings per share amounted to EUR 0.96 in the first half of 2007 (first half of 2006: EUR 0.73).

End of News DGAP News-Service  


Source:  ad-hoc-news.de

Remedium group

REMEDIUM

publishing house

CLIFAR

programmer of electronic software products

R-PRESS

advertisement agency

REPRENT

rent-a-rep company